Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

NCT03855280 is registered in ClinicalTrials.gov with Medexus Pharma, Inc. as lead sponsor.

NCT NCT03855280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03855280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Lead sponsor
Medexus Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 16, 2020
Completion date
July 4, 2022
Enrollment
21 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b